Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-25-01348 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Brian M Slomovitz und 32 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Medical Center, Miami, FL. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Peritoneal Neoplasms, Fallopian Tube Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Medical Center, Miami, FL.
- Mayo Clinic, Rochester, MN.
- Roswell Park Comprehensive Cancer Center, Buffalo, NY.
- Moffitt Cancer Center, Tampa, FL.
- Endeavor Health, NorthShore University Health System, Evanston, IL.
- The Ohio State University Comprehensive Cancer Center, Columbus, OH.
ORCID-Profile: Brian M Slomovitz, Vivek Podder, Mary Tilley Jenkins Vogel, Floor Backes, Meaghan Elizabeth Tenney, Shannon N Westin, David S Miller, Mitchell I Edelson, Eleonora Teplinsky, Michael Guy, Grace M Choong, David M O'Malley, Larry J Copeland, Thomas J Herzog, Robert L Coleman, David M Gershenson
Zitieren
APA
Slomovitz, B. M., Weroha, S. J., Deng, W., Chon, H. S., Podder, V., Jenkins Vogel, M. T., Backes, F., Thomas, E. D., Chen, L. M., Tenney, M. E., Westin, S. N., Markham, M. J., Miller, D. S., Edelson, M. I., Muller, C. Y., Callahan, M. J., Holman, L. L., Liu, J. R., Teplinsky, E., …, & Gershenson, D. M. (2026). Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01348
Vancouver
Slomovitz BM, Weroha SJ, Deng W, Chon HS, Podder V, Jenkins Vogel MT, et al. Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01348
BibTeX
@article{Slomovitz2026,
author = {Slomovitz, Brian M and Weroha, S John and Deng, Wei and Chon, Hye Sook and Podder, Vivek and Jenkins Vogel, Mary Tilley and Backes, Floor and Thomas, Eric D and Chen, Lee-May and Tenney, Meaghan Elizabeth and Westin, Shannon N and Markham, Merry Jennifer and Miller, David S and Edelson, Mitchell I and Muller, Carolyn Y and Callahan, Michael J and Holman, Laura L and Liu, J Rebecca and Teplinsky, Eleonora and Kamat, Aparna and Guy, Michael and Chern, Jing-Yi and Lea, Jayanthi and Murphy, Martina and Choong, Grace M and Moore, Elena D and Alvarez, Edwin A and Rodgers, William H and O'Malley, David M and Copeland, Larry J and Herzog, Thomas J and Coleman, Robert L and Gershenson, David M},
title = {Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-25-01348}
}
EUVIMED